ImmunityBio Inc IBRX 深 滬
等待開盤 03-26 09:30:00 美东时间
8.07
+0.655
+8.83%
華盛通- 最 高8.35
- 今 開7.75
- 成交量 2903.91万股
- 最 低 7.45
- 昨 收 7.415
- 總市值 82.97亿
- 52周最高 12.43
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.83
- 委 比 57.70%
- 總股本 10.28亿
- 歷史最高 45.42
- 量 比 0.78
- 振 幅 12.14%
- 歷史最低 0.93
- 每 手 1
- 風險率 2.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多期权扫描 | PUT单飙涨1000%+ 期权爆量3倍！Circle创历史最大单日跌幅；临期期权集体大跌，谷歌、微软、Meta看涨期权成交活跃
PUT单飙涨1000%+ 期权爆量3倍！Circle创历史最大单日跌幅；临期期权集体大跌，微软、谷歌期权成交持续放量，看涨期权占比超60%>>
03-25 19:24
FDA Issues Warning To ImmunityBio Over Misleading Anktiva Promotions, Says False & Misleading Claims/Misbranded
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/immunitybio-inc-725468-03132026
03-24 21:37
Top performing mid-cap stocks YTD as volatility hits markets
U.S. mid-cap stocks have delivered solid year-to-date performance amid favorable economic conditions and broadening market participation, despite recent volatility due to geopolitical challenges. In l...
03-24 02:47
ImmunityBio gains as NCCN guidelines include new Anktiva indication
ImmunityBio (IBRX) added ~7% in the premarket on Wednesday after the company announced that the National Comprehensive Cancer Network has updated its treatment guidelines to include an expanded use of...
03-17 20:07
ImmunityBio cites QUILT-3.032 data as NCCN adds ANKTIVA plus BCG for BCG-unresponsive papillary-only NMIBC
ImmunityBio cites QUILT-3.032 data as NCCN adds ANKTIVA plus BCG for BCG-unresponsive papillary-only NMIBC ImmunityBio reported that the NCCN updated its 2026 bladder cancer guidelines to include ANKTIVA (nogapendekin alfa inbakicept-pmln) plus BCG for patients with BCG-unresponsive non-muscle invas
03-17 19:30
ImmunityBio rises after updates on cell therapy programs
ImmunityBio (IBRX) shares gained on Friday after the cancer drug developer announced the successful conclusion of two manufacturing engineering programs designed to validate its Cytokine-Enriched NK C...
03-14 01:03
Why Is ImmunityBio Stock Soaring On Friday?
ImmunityBio stock rises in premarket after NK cell therapy trials show safety and scalable production of billions of cells.
03-13 22:44
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
BTIG Assumes ImmunityBio at Buy, Announces Price Target of $13
BTIG analyst Jeet Mukherjee assumes ImmunityBio (NASDAQ:IBRX) with a Buy rating and announces Price Target of $13.
03-12 18:56
Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets
Lucid, CleanSpark and Hims & Hers are the top 3 most shorted stocks. Here's the rest of the top ten.
03-12 03:20
